A recent FDA-approved drug, sotagliflozin, has shown significant promise in reducing heart attacks and strokes in patients with diabetes and kidney disease. The study, led by Mount Sinai researcher Deepak L. Bhatt, found that sotagliflozin reduces the risk of heart attack and stroke by 23% compared to a placebo.
Sotagliflozin is an SGLT inhibitor that targets both SGLT1 and SGLT2 proteins, regulating blood sugar levels by transporting glucose and sodium across cell membranes. The unique mechanism of action involves blocking both receptors, reducing the risk of cardiovascular events.
The SCORED clinical trial, led by Dr. Bhatt, analyzed 10,584 patients with chronic kidney disease, type 2 diabetes, and additional cardiovascular risk factors. Patients were randomly assigned to sotagliflozin or a placebo and followed for an average of 16 months. The results showed that sotagliflozin significantly reduced the risk of heart attacks, strokes, and deaths from cardiovascular causes.
This breakthrough study offers new hope for patients with diabetes and kidney disease, providing a potential solution for reducing global cardiovascular risk. With its unique mechanism of action, sotagliflozin could become a widely used treatment option to protect against heart attack and stroke.
Source: https://scitechdaily.com/new-fda-approved-diabetes-drug-slashes-heart-attack-and-stroke-risk